Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
In this installment of Fueling GIST Research, Dr. César Serrano shares on the importance of GIST research & collaboration among institutions to build a vision of new treatments & a cure.
Our Spring to GIST Awareness Day Campaign Continues! Our spring fundraising campaign is all about Fueling GIST Research and we will be sharing examples of all the ways The Life Raft Group is involved [...]
Our Spring to GIST Awareness Day Campaign Continues! Our spring fundraising campaign is all about Fueling GIST Research and we will be sharing examples of all the ways The Life Raft Group is involved [...]
NCCN recently updated the clinical practice guidelines in oncology for medical professionals for several types of cancer including GIST. These guidelines are a set of evidence-based recommendations for the diagnosis, treatment, and management of various types of cancer and define the recommendations for management, care, and treatment of all cancers in the US. What do you need to know?
If you didn't find what you were looking for, try a new search!
